GlobeNewswire by notified

TGS, BGP, CGG Commence Acquisition of Suriname 3D Phase 1

Share

OSLO, Norway (11 November 2021) – Further to the announcement on October 20, 2021, of a signed agreement with Staatsolie for multi-client programs offshore Suriname, TGS, acting as the marketing and licensing lead in a consortium with CGG and BGP, today announced that acquisition for Phase 1 of the Suriname 3D project has commenced.

This 3D survey is adjacent to the prolific Block 58 and will cover the up-dip portions of the same Upper Cretaceous channel systems proven successful recently.

Phase 1 includes 11,100 square kilometers of new 3D seismic data acquisition and 3,000 square kilometers of 3D seismic data reprocessing. The acquisition will be undertaken by the BGP Prospector.

CGG will process all of this multi-client data in its Houston subsurface imaging center using a high-end depth imaging workflow, including its proprietary technologies: Time-Lag Full-waveform Inversion (TLFWI) and High-frequency FWI Imaging.

Early products will be available from April 2022 with final TTI Kirchhoff PSDM products ready from November 2022. 

This project is supported by industry funding.

About TGS
TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions.

Forward Looking Statement
All statements in this press release other than statements of historical fact are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include TGS' reliance on a cyclical industry and principal customers, TGS' ability to continue to expand markets for licensing of data, and TGS' ability to acquire and process data product at costs commensurate with profitability, as well as volatile market conditions, which have been exacerbated by the COVID-19 pandemic and the severe drop in oil prices.  Actual results may differ materially from those expected or projected in the forward-looking statements. TGS undertakes no responsibility or obligation to update or alter forward-looking statements for any reason.

For more information, visit TGS.com or contact:

Sven Børre Larsen
CFO
+47 90 94 36 73
investor@tgs.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update8.5.2024 22:15:38 CEST | Press release

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trial Zeno BLA accepted for priority review by the FDA for the treatment of NRG1+ NSCLC and PDACBased on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter and provided a business update. “At the upcoming 2024 ASCO meeting, we are looking forward to presenting multiple datasets including the first clinical data on safety and efficacy of petosemtamab in combination with pembrolizumab in previously untreated head and neck cancer. With p

CrossAmerica Partners LP Reports First Quarter 2024 Results8.5.2024 22:15:00 CEST | Press release

Allentown, PA, May 08, 2024 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Reports First Quarter 2024 Results Reported First Quarter 2024 Net Loss of $17.5 million that includes a $15.9 million loss on lease terminations with Applegreen, Adjusted EBITDA of $23.6 million and Distributable Cash Flow of $11.7 million compared to a Net Loss of $1.0 million, Adjusted EBITDA of $31.7 million and Distributable Cash Flow of $19.1 million for the First Quarter 2023Reported First Quarter 2024 Gross Profit for the Wholesale Segment of $27.0 million compared to $31.2 million of Gross Profit for the First Quarter 2023 and First Quarter 2024 Gross Profit for the Retail Segment of $54.4 million compared to $50.8 million of Gross Profit for the First Quarter 2023Leverage, as defined in the CAPL Credit Facility, was 4.49 times as of March 31, 2024, compared to 4.21 times as of December 31, 2023The Distribution Coverage Ratio for the trailing twelve months ended March 31, 2024 was 1.37 times compared to 1

Oculis Reports Q1 2024 Financial Results and Provides Company Updates8.5.2024 22:10:00 CEST | Press release

ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED); RELIEF topline results anticipated in Q2 2024Completed $59 million registered direct equity offering and concurrent listing on Nasdaq Iceland Main Market in April 2024, extending cash runway into the second half of 2026Strengthened executive leadership team and U.S. presence with the appointments of accomplished and seasoned professionals as President of Research & Development and Chief Human Resources Officer Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the three-month period ended March 31, 2024, and an overview of the Company’s progress. Riad Sherif M.D., Chief

Nokia Corporation: Repurchase of own shares on 08.05.20248.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 08 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 08.05.2024 Espoo, Finland – On 08 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,9483.49CEUX--BATE--AQEU--TQEX--Total362,9483.49 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Trading in GN Store Nord shares by board members, executives and associated persons8.5.2024 21:28:31 CEST | Press release

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them. Details of the person discharging managerial responsibilities/person closely associated Name Jørgen Bundgaard Hansen Reason for the notification Position/status Member of the Board of Directors Initial notification/Amendment Initial notification Details of the issuer Name GN Store Nord A/S LEI 5493008U3H3W0NKPFL10 Details of the transaction(s) Description of the financial instrument, type of instrument Identification code Shares DK0010272632 Nature of the transaction Purchase of shares Price(s) and volume(s) Price(s) DKK 201.0 DKK 201.1 DKK 201.1 DKK 201.0 DKK 201.0 DKK 201.0 DKK 201.1 DKK 201.1 DKK 201.2 DKK 201.2 DKK 201.2 DKK 201.0 DKK 201.3 DKK 201.2 DKK 201.2 DKK 201.2 DKK 201.2 DKK 201.2 DKK 201.3 DKK 201.5 DKK

HiddenA line styled icon from Orion Icon Library.Eye